Aoxin Tianli Group, Inc. announced unaudited consolidated earnings results for third quarter and nine months ended Sept. 30, 2016. For the quarter, the company reported revenues of 7,841,371, loss from operations of 90,149, loss before income taxes of 1,783,060, net loss from continuing operations of 1,783,060 or $0.22 basic and diluted per share, net gain attributable to company of 2,707,347 compared to the revenues of 9,176,510, income from operations of 1,846,501, income before income taxes of 1,103,476, net income from continuing operations of 1,103,476 or $0.13 basic and diluted per share, net gain attributable to company of 875,004 for the same quarter a year ago. For the year to date, the company reported revenues of 26,511,428, income from operations of 2,112,938, income before income taxes of 570,141, net income from continuing operations of 570,141 or $0.07 basic and diluted per share, net gain attributable to company of 2,133,686 compared to the revenues of 28,616,426, income from operations of 2,492,068, income before income taxes of 1,707,343, net income from continuing operations of 1,707,343 or $0.21 basic and diluted per share, net gain attributable to company of 1,554,455 for the same period a year ago. Net cash provided by operating activities was $9,987,746 against $13,676,853 a year ago. Purchase of biological assets was $106,379 against $49,894 a year ago. Purchase of plant and equipment was $2,988,644 against $2,772 a year ago.